Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of growth hormone, strontium ranelate and phosphate on PTH rhythm and bone metabolism in postmenopausal women with low BMD
2005-004316-73Phase 4Completed
- Sponsor
- Royal Liverpool University Hospital
- Start
- Dec 2005
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of somatropin, strontium ranelate and sodium acid phosphate in osteoporosis and low bone mineral density (3 arms), sponsored by Royal Liverpool University Hospital. Primary endpoint: Difference in PTH circadian rhythm. Started Dec 2005; status: completed.
02
Drugs
somatropinstrontium ranelatesodium acid phosphate
03
Conditions
osteoporosislow bone mineral density
Beyond the preview
Go deeper on 2005-004316-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004316-73.